Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Genetic Disease
Study Phase : Approved
Sponsor : Teva Pharmaceutical Industries
Deal Size : Undisclosed
Deal Type : Partnership
Teva and Jiangsu Nhwa Partner to Promote AUSTEDO® Access in China
Details : The partnership focuses on commercializing Teva’s Austedo (deutetrabenazine), FDA-approved for treating tardive dyskinesia and chorea associated with Huntington’s disease.
Brand Name : Austedo
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 26, 2024
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Sponsor : Teva Pharmaceutical Industries
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Oliceridine
Therapeutic Area : Neurology
Study Phase : Approved
Recipient : Trevena
Deal Size : $5.5 million
Deal Type : Licensing Agreement
Trevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical
Details : Under the license agreement, Nhwa granted a license to develop, manufacture, and commercialize Olinvyk (oliceridine), an opioid medication that is used for the treatment of moderate to severe acute pain in adults, in China.
Brand Name : Olinvyk
Molecule Type : Small molecule
Upfront Cash : $2.5 million
May 31, 2023
Lead Product(s) : Oliceridine
Therapeutic Area : Neurology
Highest Development Status : Approved
Recipient : Trevena
Deal Size : $5.5 million
Deal Type : Licensing Agreement
Complix Discovery Development Agreement Jiangsu Develop Alphabody Therapeutics
Details : Under the terms of the agreement, Complix has granted an exclusive license to Nhwa to develop, manufacture and commercialize the CPABs resulting from this collaboration in Greater China.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 28, 2021
LOOKING FOR A SUPPLIER?
Reset All
